• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Dasatinib - Key patent, SPC, and data exclusivity expiry (44 country coverage) Product Image

Dasatinib - Key patent, SPC, and data exclusivity expiry (44 country coverage)

  • ID: 1532806
  • November 2014
  • Genericsweb Pty Ltd – Ark Patent Intelligence

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.

This Pipeline Selector report covers Dasatinib
Dasatinib indications: Antineoplastic; Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia
Dasatinib innovator: Bristol-Myers Squibb (Sprycel)

Examples of information found in this online report include:
- Includes key patent publications for 44 countries (see list below)
- Contains SPC protection for every EU state plus patent term extensions in other countries
- Data exclusivity calculated on a country by country basis
- Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
- DMF & Paragraph IV filings
- Litigation alerts
- Marketing authorisation holders in selected territories
- Patent risk analysis via graphical display of data from patent filings
- Hyper-linking to crucial patent documents and national registries enabling data verification

The 'Key Patent READ MORE >

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos